CUL4A and neoplasm: Although additional experiments will be required to validate that these genes are viable drug targets for this tumor subtype as they are for breast cancer cell lines (Marcotte et al., 2012; Koh et al., 2012), we propose that Cul4a is an attractive candidate because CUL4A amplification and overexpression have been observed in the human basal-like breast cancer subtype and were demonstrated to drive tumorigenesis both in vitro and in vivo (Chen et al., 1998; Gupta et al., 2002; Saucedo-Cuevas et al., 2014).